The role of IL17B-IL17RB signaling pathway in breast cancer

Alinejad, Vahideh; Dolati, Sanam; Motallebnezhad, Morteza; Yousefi, Mehdi

doi:10.1016/j.biopha.2017.01.120

Cited by 59 publications

(45 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a proinflammatory cytokine, IL-17 plays a role in host defense, immune surveillance, and regulation of tumor growth [18, 19]. Elevation of IL-17 expression has been demonstrated in a variety of malignancies, including ovarian cancer, hepatocellular carcinoma, breast cancer, prostate cancer, esophageal and gastric cancer, and non-melanoma skin cancers [9, 18, 20, 21]. However, the role of IL-17 in NPC remains relatively unknown.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-135a Inhibits Nasopharyngeal Carcinoma Cell Proliferation Through Targeting Interleukin-17

Wang

Kang

Yang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The objective of this study was to investigate the potential role of IL-17 in the development of nasopharyngeal carcinoma (NPC) and to screen microRNAs (miRNAs) that potentially target IL-17 in NPC cells. Methods: Blood was collected from NPC patients and normal subjects, and plasma IL-17 concentration was quantified by enzyme-linked immunosorbent assay. An immortalized normal human nasopharyngeal epithelial cell line, NP69, was treated with or without human IL-17 (15 ng/mL) for various times, and expression of IL-1ß, IL-6, IL-12, and TNF-α mRNA was assessed by real-time reverse transcription PCR. The candidate miRNAs that potentially target IL-17 were predicted by a bioinformatics strategy. The selected miR-135a mimic was transfected into primary NPC cells, and cell proliferation was assessed by MTT assay. Results: The concentration of plasma IL-17 was significantly higher in the NPC patients (92.5 ± 7.3 pg/mL) than in the control subjects (56.8 ± 2.9 pg/mL). In response to IL-17 treatment, the mRNA expression of IL-1ß and IL-6 was significantly upregulated and reached a peak at 12 h, followed by a slight decrease at 24 h, while the mRNA expression of IL-12 and TNF-α was significantly upregulated at 12 h and remained high even at 48 h after exposure to IL-17. Moreover, miR-135a specifically targets IL-17 and was dramatically downregulated in NPC cells compared with NP69 cells. Transfection of exogenous miR-135a mimic resulted in significant suppression of IL-17 secretion and subsequent inhibition of NPC cell proliferation. Conclusions: Blood IL-17 was significantly higher in NPC patients compared with normal subjects. Expression of miR-135a in the cancer cells isolated from nasopharyngeal tumors was significantly lower than that in NP69 cells, and suppression of IL-17 by miR-135a mimic resulted in significant inhibition of NPC cell proliferation. These findings suggested that downregulation of miR-135a may contribute to the development of NPC via the mechanism of IL-17 stimulation of proinflammatory cytokine expression.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-135a Inhibits Nasopharyngeal Carcinoma Cell Proliferation Through Targeting Interleukin-17

Wang

Kang

Yang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Data suggesting the promoting or inhibiting role of Th-17 and IL-17 on tumorigenesis have been reported. Some findings (Alinejad et al 2017) have suggested that through activation of the ERK1/ERK2, NF-kb and BCL-2 pathways, the IL-17B/IL-17RB system promotes inflammation, breast cancer progression as well as resistance to chemotherapy drugs (Alinejad et al 2016). Conversely, some findings have shown that IL-17 significantly induce MDSC differentiation, inhibit their proliferation and trigger apoptosis through the JAK/STAT3 pathway in vitro (Ma et al 2018), whereas other findings (Benchetrit et al 2002, Kryczek et al 2009 have supported an anti-tumour effect against certain tumours.…”

Section: Sex Hormones and The Immune Responsementioning

confidence: 99%

Tumour growth and immune evasion as targets for a new strategy in advanced cancer

Nicolini¹,

Rossi²,

Carpi³

2018

Endocrine-Related Cancer

View full text Add to dashboard Cite

It has become clearer that advanced cancer, especially advanced breast cancer, is an entirely displayed pathological system that is much more complex than previously considered. However, the direct relationship between tumour growth and immune evasion can represent a general rule governing the pathological cancer system from the initial cancer cells to when the system is entirely displayed. Accordingly, a refined pathobiological model and a novel therapeutic strategy are proposed. The novel therapeutic strategy is based on therapeutically induced conditions (undetectable tumour burden and/or a prolonged tumour 'resting state'), which enable an efficacious immune response in advanced breast and other types of solid cancers.

show abstract

“…Numerous factors contribute to the progression of breast cancer, including inflammation. The IL17 family consist of six protein members, among them IL17B and its receptor; and the IL17RB signaling pathway plays a key role in development and progression of breast cancer [15,16]. Eotaxin, CXCL10, S100A7, S100A8, S100A9, MMP1, and MMP13 were up-regulated and IL-17B was down-regulated.…”

Section: Discussionmentioning

confidence: 99%

RNA-Sequence Analysis Reveals Differentially Expressed Genes (DEGs) in Patients Exhibiting Different Risks of Tumor Metastasis

Dong

Long

et al. 2017

Med Sci Monit

View full text Add to dashboard Cite

BackgroundBreast cancer is one of the most common malignancies in women. In a previous study, we found that for two patients who had a high risk of lymphatic metastasis, lymphatic metastasis did not occur; whereas, for two patients who had a low risk of lymphatic metastasis, lymphatic metastasis did occur.Material/MethodsWe analyzed the differential gene expressions of these four patients by RNA-sequence. The data (HRNM_T versus HRNM_N, LRYM_T versus LRYM_N, and HRNM_T versus LRYM_T) was then processed using differentially expressed genes (DEGs) analysis, functional analysis for DEGs, and PPI network construct.ResultsFor HRNM_T versus HRNM_N, there were 224 DEGs. There were 504 DEGs for LRYM_T versus LRYM_N, and 88 DEGs for LRYM_T versus LRYM_N. For HRNM_T versus HRNM_N, DEGs were up-regulated mainly in the cell cycle, the IL-17 signaling pathway, and the progesterone-mediated oocyte maturation; DEGs were down-regulated mainly in the IL-17 signaling pathway. For LRYM_T versus LRYM_N, DEGs were up-regulated mainly in protein digestion and absorption, and cytokine-cytokine receptor interaction; DEGs were down-regulated mainly in ECM-receptor interaction. For HRNM_T versus LRYM_T, DEGs were up-regulated mainly in the PPAR signaling pathway; DEGs were downregulated mainly in the adipocytokine signaling pathway. The DEGs were screened to construct PPI networks.ConclusionsThe GO and KEGG functional enrichments of HRNM_T versus HRNM_N, and LRYM_T versus LRYM_N were consistent with earlier studies. For HRNM_T versus LRYM_T, DEGs were up-regulated mainly in PPAR signaling; DEGs were down-regulated mainly in the adipocytokine pathway.

show abstract

The role of IL17B-IL17RB signaling pathway in breast cancer

Cited by 59 publications

References 104 publications

MicroRNA-135a Inhibits Nasopharyngeal Carcinoma Cell Proliferation Through Targeting Interleukin-17

MicroRNA-135a Inhibits Nasopharyngeal Carcinoma Cell Proliferation Through Targeting Interleukin-17

Tumour growth and immune evasion as targets for a new strategy in advanced cancer

RNA-Sequence Analysis Reveals Differentially Expressed Genes (DEGs) in Patients Exhibiting Different Risks of Tumor Metastasis

Contact Info

Product

Resources

About